Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization
| Status: | Recruiting |
|---|---|
| Conditions: | Liver Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | November 7, 2017 |
| End Date: | November 7, 2020 |
| Contact: | Rosy Diaz |
| Email: | Rosaura.diaz@med.usc.edu |
| Phone: | 323-442-7469 |
The Role of Quantitative Contrast-Enhanced Ultrasound in Yttrium-90 (90Y) Radioembolization of Hepatocellular Carcinoma
This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing
patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced
ultrasound may provide detailed imaging of the tumor arteries after the injection of a
contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit
in the tumor.
patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced
ultrasound may provide detailed imaging of the tumor arteries after the injection of a
contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit
in the tumor.
PRIMARY OBJECTIVES:
I. Investigate the relationship between hepatocellular carcinoma (HCC) tumor perfusion on
pre-procedural contrast-enhanced ultrasound (CEUS) time intensity curve (TIC) and
post-procedural Yttrium-90 (90Y) microsphere distribution after 90Y radioembolization (RE).
SECONDARY OBJECTIVES:
I. Study the potential of serial CEUS TIC examinations as a marker of tumor treatment
response as assessed at 20 - 24 week computed tomography (CT) follow-up.
OUTLINE:
Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at
baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo positron emission
tomography/computed tomography (PET/CT) after standard of care 90Y radioembolization at
baseline.
I. Investigate the relationship between hepatocellular carcinoma (HCC) tumor perfusion on
pre-procedural contrast-enhanced ultrasound (CEUS) time intensity curve (TIC) and
post-procedural Yttrium-90 (90Y) microsphere distribution after 90Y radioembolization (RE).
SECONDARY OBJECTIVES:
I. Study the potential of serial CEUS TIC examinations as a marker of tumor treatment
response as assessed at 20 - 24 week computed tomography (CT) follow-up.
OUTLINE:
Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at
baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo positron emission
tomography/computed tomography (PET/CT) after standard of care 90Y radioembolization at
baseline.
Inclusion Criteria:
- Patients scheduled for 90Y radioembolization for HCC as part of their standard of care
Exclusion Criteria:
- Patients who have already received tumor treatment (either systemic or loco-regional
such as previous Y90RE, microwave or radiofrequency [RF] ablation or transarterial
chemoembolization [TACE])
- Pregnant or nursing
- Known cardiac shunt
- Known pulmonary hypertension
- History of hypersensitivity to Definity (perflutren lipid microsphere) or Lumason
- History of hypersensitivity to iodinated contrast agent
- Cannot consent for himself or herself
We found this trial at
1
site
1441 Eastlake Ave
Los Angeles, California 90033
Los Angeles, California 90033
(323) 865-3000
Phone: 323-442-7469
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Click here to add this to my saved trials
